Jeremie Vitte

Affiliations: 
University of California, Los Angeles, Los Angeles, CA 
Area:
Neuro-oncology
Google:
"Jeremie Vitte"
Mean distance: (not calculated yet)
 

Parents

Sign in to add mentor
Judith Melki grad student
Alexis Brice post-doc
Marco Giovannini research scientist
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Staedtke V, Anstett K, Bedwell D, et al. (2023) Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials (London, England). 17407745231207970
Chiasson-MacKenzie C, Vitte J, Liu CH, et al. (2023) Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature Communications. 14: 1559
Roberts DS, Maurya R, Takemon Y, et al. (2019) Linked-read Sequencing Analysis Reveals Tumor-specific Genome Variation Landscapes in Neurofibromatosis Type 2 (NF2) Patients. Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 40: e150-e159
Fuse MA, Dinh CT, Vitte J, et al. (2019) Preclinical Assessment of MEK1/2 Inhibitors for Neurofibromatosis Type 2-Associated Schwannomas Reveal Differences in Efficacy and Drug Resistance Development. Neuro-Oncology
Osum S, Stemmer-Rachamimov A, Widemann B, et al. (2019) TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1 Neuro-Oncology. 21: vi267-vi267
Vitte J, Gao F, Coppola G, et al. (2019) TMOD-15. SPATIOTEMPORAL LOSS OF SMARCB1 IN EARLY NEURAL CREST LINEAGE LEADS TO DIFFERENT MOLECULAR SUBTYPES OF RHABDOID TUMORS Neuro-Oncology. 21: ii124-ii124
Isakson SH, Rizzardi AE, Coutts AW, et al. (2018) Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology. 1: 158
Paganini I, Capone GL, Vitte J, et al. (2017) Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma. Journal of Neuro-Oncology
Vitte J, Gao F, Coppola G, et al. (2017) Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature Communications. 8: 300
Shi Y, Bollam SR, White SM, et al. (2016) Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Developmental Cell
See more...